Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.

European journal of medicinal chemistry - 1 Oct 2020

Wu Wei-Cheng, Liu Yi-Min, Liao Yu-Hsuan, Hsu Kai-Cheng, Lien Ssu-Ting, Chen I-Chung, Lai Mei-Jung, Li Yu-Hsuan, Pan Shiow-Lin, Chen Mei-Chuan, Liou Jing-Ping

Abstract excerpt

A major cause of failure of therapy in patients with non-small cell lung cancer (NSCLC) is development of acquired drug resistance leading to tumor recurrence and disease progression. In addition to the development of new generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), different molecular targets may provide opportunities to improve the therapeutic outcomes. In this study,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caspases

Share to Cytoprotection

Share to Enzyme Activation

Share to Inhibitory Concentration 50

Share to Proteolysis

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 32683166
DOI: 10.1016/j.ejmech.2020.112540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.PMID 32683166Read ↗

Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.Semantic proximity Read ↗

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protractionSemantic proximity Read ↗

HSP90 inhibitors in lung cancer: promise still unfulfilled.Semantic proximity Read ↗

A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effectsSemantic proximity Read ↗

Development of Novel Class of Phenylpyrazolo[3,4-d]pyrimidine-Based Analogs with Potent Anticancer Activity and Multitarget Enzyme Inhibition Supported by Docking Studies.Semantic proximity Read ↗

Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A ReviewSemantic proximity Read ↗

Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFRWT/EGFRT790M inhibitors.Semantic proximity Read ↗

HSP90: A promising target for NSCLC treatments.Semantic proximity Read ↗

Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.Semantic proximity Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.